Skip to main content

Table 1 Baseline characteristics of the study population and univariable effects on mortality

From: Predictors of in-hospital mortality in diabetic patients with non-ST-elevation myocardial infarction

Characteristic

Total

Alive

Dead

OR

95% CI

P value

Lower

Upper

Age (y), mean (SD)

64.7 (10.59)

64.5 (10.53)

69.8 (10.9)

1.05

1.03

1.07

0.001

Sex (male), n (%)

1787 (57.0)

1725(57.2)

62 (53.0)

0.84

0.58

1.22

0.368

Hypertension, n (%)

2200 (70.2)

2130 (70.6)

70 (59.8)

0.62

0.42

0.90

0.013

Dyslipidemia, n (%)

2020 (64.5)

1954 (64.9)

66 (56.4)

0.70

0.48

1.01

0.062

Family history, n (%)

261 (8.5)

255 (8.6)

6 (5.5)

0.61

0.26

1.40

0.247

COPD, n (%)

44 (1.4)

40 (1.3)

4 (3.4)

2.63

0.92

7.48

0.070

CABG, n (%)

553 (17.7)

532 (17.7)

21 (17.9)

1.02

0.63

1.65

0.934

Previous MI, n (%)

524 (17.0)

504 (16.9)

20 (17.2)

1.02

0.62

1.66

0.933

RF, n (%)

317(10.1)

289 (9.6)

28 (23.9)

2.96

1.90

4.61

 < 0.001

LVEF, n (%)

       

 Normal

470 (18.4)

463 (18.8)

7 (7.4)

   

 < 0.001

 Mild reduction

459 (18.0)

540 (18.3)

9 (9.6)

1.32

0.48

3.58

0.582

 Moderate reduction

1044 (40.8)

1013 (41.1)

31 (33.0)

2.02

0.88

4.63

0.095

 Severe reduction

583 (22.8)

536 (21.8)

47 (50.0)

5.80

2.59

12.95

 < 0.001

ACEI/ARB, n (%)

1356 (45.7)

1313 (46.0)

43 (37.7)

0.71

0.48

1.04

0.084

Aspirin, n (%)

2239 (95.8)

2197 (95.9)

42 (93.3)

0.60

0.18

1.98

0.408

Clopidogrel, n (%)

1108 (85.6)

1087 (85.8)

21 (77.8)

0.58

0.23

1.45

0.246

Statin, n (%)

1920 (88.0)

1886 (88)

34 (82.9)

0.65

0.28

1.50

0.322

Body mass index (kg/m2), n (%)

27.9 (4.65)

27.9 (4.63)

28.3 (5.97)

1.01

0.95

1.08

0.615

Cigarette smoking, n (%)

       

 Current

2350 (75.8)

2255 (75.6)

95 (981.2)

   

0.320

 Former

294 (75.8)

287 (9.6)

7 (6.0)

0.57

0.26

1.26

0.168

 Never

455 (14.7)

440 (14.8)

15 912.8)

0.80

0.46

1.40

0.454

Opium, n (%)

       

 Current

2897 (92.5)

2784 (92.4)

113 (96.6)

   

0.403

 Former

33 (1.1)

33 (1.1)

0 (0.0)

   

0.998

 Never

201 (6.4)

197 (6.5)

4 (3.4)

0.50

0.18

1.37

0.178

Diabetes treatment, n (%)

       

 Diet

174 (5.6)

169 (5.7)

5 (4.6)

0.55

0.19

1.59

0.275

 Oral

1854 (59.9)

1805 (60.5)

49 (45.4)

0.51

0.27

0.95

0.036

 Insulin

674 (20.9)

613 (20.5)

34 (31.5)

1.04

0.54

2.01

0.895

 Combination

160 (5.2)

153 (5.1)

79 (6.5)

0.86

0.33

2.20

0.757

Total cholesterol, median

165 (134, 198)

165 (134, 198)

160.5 (133, 204)

0.9

0.99

1.00

0.717

Triglyceride, median

149 (106, 213)

149 (106, 213)

137.5 (94, 183)

0.99

0.99

1.00

0.267

HDL, median

38.5 (10.57)

38.5 (10.58)

36.8 (10.14)

0.98

0.95

1.01

0.321

LDL, median

99 (74, 126)

99 (74, 126)

99 (70, 127)

1.00

0.99

1.00

0.943

Creatinine (mg/dL), median

1.0 (0.8, 1.2)

1.0 (0.8, 1.2)

1.1 (0.8, 1.6)

1.20

0.99

1.45

0.051

HbA1C, n (%)

8.2 (7.1, 9.5)

8.8 (7.2, 10.1)

1.135

0.94

1.36

0.18

0.178

Hemoglobin (mg/dL), n (%)

13.8 (2.03)

13.8 (2.03)

13.2 (2.01)

0.86

0.73

1.02

0.098

  1. Continuous variables are presented as the mean (SD) or the median (25th and 75th percentiles)
  2. Categorical variables are described as frequencies (percentages); n (%)
  3. COPD chronic obstructive pulmonary disease, CABG coronary artery bypass graft, MI myocardial infarction, RF renal failure, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, HDL high-density lipoprotein, LDL low-density lipoprotein